Rigel Pharmaceuticals Inc (RIGL)
EBITDA Growth
-59.64%
Quarterly · Period ending:
RIGL EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-59.64%period ending
Latest reported-59.64%period ending
RIGL Quarterly EBITDA YoY % (-185.07% → -59.64%)
Year-over-year change
High-resolution chart · PNG
RIGL ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -59.6369% | |
| -2.0117% | |
| 40.6783% | |
| 99.5561% | |
| 3,774.8759% | |
| 333.8523% | |
| 505.4137% | |
| 531.0768% | |
| 136.29% | |
| 50.1211% | |
| 5.1934% | |
| 80.5186% | |
| 64.985% | |
| 53.9476% | |
| 113.2965% | |
| 7.8883% | |
| 0.6889% | |
| -161.9193% | |
| -12.8803% | |
| -43.6672% | |
| 25.1187% | |
| 94.8181% | |
| -11.4359% | |
| -20.0071% | |
| 16.5125% | |
| 223.6435% | |
| -719.4063% | |
| 52.0651% | |
| 21.2662% | |
| 29.1905% | |
| 110.3249% | |
| -33.0497% | |
| -34.9558% | |
| -53.1538% | |
| -66.8499% | |
| -5.8967% | |
| -43.6361% | |
| 6.768% | |
| -26.0698% | |
| -158.0074% | |
| 1.5226% | |
| 3.1619% | |
| 43.2368% | |
| 68.2693% | |
| 45.2543% | |
| 18.058% | |
| -24.7062% | |
| 5.2807% | |
| -11.5739% | |
| 13.2223% | |
| 28.2821% | |
| 13.3432% | |
| 8.3017% | |
| -10.0316% | |
| 3.2267% | |
| -42.1956% | |
| -15.1369% | |
| -11.4878% | |
| -50.1218% | |
| -134.5347% | |
| -177.3047% | |
| 7.403% | |
| 31.9102% | |
| 293.4875% | |
| 192.5442% | |
| 25.5614% | |
| 26.5654% | |
| 31.5331% | |
| 15.5891% | |
| -4.2672% | |
| -68.9037% | |
| -90.772% | |
| -72.237% | |
| -58.6583% | |
| -20.9961% | |
| -61.9981% | |
| -518.1153% | |
| -88.7799% | |
| -71.4033% | |
| 9.2359% | |
| 73.458% | |
| 14.7059% | |
| 32.2758% | |
| 13.6665% | |
| -3.0359% | |
| 11.0062% | |
| -26.4171% | |
| -52.9474% | |
| -25.7077% | |
| -90.9077% | |
| -69.6915% | |
| -17.0588% | |
| -5.6842% | |
| 2.5465% | |
| -47.8864% | |
| -84.8599% | |
| -47.7087% | |
| -136.6103% | |
| 87.4102% | |
| -243.3453% |